Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 8/20 | 0.46 |
| ▸ | DRD3 | P35462 | 7/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | YES1 | P07947 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CSK | P41240 | 1/20 | 0.43 |
| ▸ | BLK | P51451 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227724 | 0.83 | SRC (0.46) | SRCBRAFDRD2DRD3ABL1 | |
| SCHEMBL230249 | 0.80 | SRC (0.77) | SRCBRAFABL1EGFRRAF1 | |
| SCHEMBL5501154 | 0.79 | SRC (0.69) | SRCBRAFABL1EGFRRAF1 | |
| SCHEMBL5501445 | 0.77 | MAP4K1 (0.64) | SRCEGFRFGFR1 | |
| SCHEMBL226225 | 0.76 | SRC (0.55) | SRCBRAFABL1LCKYES1 | |
| SCHEMBL226380 | 0.74 | STK17A (0.58) | PDGFRBFGFR1 | |
| SCHEMBL2573807 | 0.74 | SRC (0.53) | SRCBRAFLCKYES1FGFR1 | |
| SCHEMBL229526 | 0.73 | ALK (0.59) | EGFR | |
| SCHEMBL229260 | 0.72 | BRAF (0.48) | SRCBRAFABL1RAF1LCK | |
| SCHEMBL2573809 | 0.72 | YES1 (0.53) | SRCBRAFABL1LCKYES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | claimed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | claimed |
| EP-2381943-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | Fovea Pharmaceuticals (FR) | 2011-11-02 | — | — | EP | claimed |
| WO-2010076238-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA (FR) | 2010-07-08 | — | — | WO | claimed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | SRC 1325/4885BRAF 50/4885DRD2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.